DISCLAIMER

Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.

Research Market strategy
by Swissquote Analysts
China's second-quarter GDP growth beat market expectations thanks to a strong industrial recovery, but the momentum will likely weaken in the second half of the year, JPMorgan economist Zhu Haibin says. External uncertainties, including the pace of the global recovery and U.S.-China ties, will...
16.07.2020
US equities continued to rally on Wednesday, regurgitating the news about Moderna’s COVID-19 vaccine. Goldman Sachs’ upbeat reporting also gave the stock markets a boost. The S&P 500 (+0.91%) has performed better than tech-oriente...
16.07.2020
Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp. The two companies will develop pralsetinib, a therapy for people with RET-altered nonsmall cell lung cancer, various types of thyroid cancer and other solid tumours.
15.07.2020
Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp. The two companies will develop pralsetinib, a therapy for people with RET-altered nonsmall cell lung cancer, various types of thyroid cancer and other solid tumours. The...
14.07.2020
 
在線聊天